162 related articles for article (PubMed ID: 25182125)
21. Intact Doxil is taken up intracellularly and released doxorubicin sequesters in the lysosome: evaluated by in vitro/in vivo live cell imaging.
Seynhaeve ALB; Dicheva BM; Hoving S; Koning GA; Ten Hagen TLM
J Control Release; 2013 Nov; 172(1):330-340. PubMed ID: 24012486
[TBL] [Abstract][Full Text] [Related]
22. A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer.
Adams SF; Marsh EB; Elmasri W; Halberstadt S; Vandecker S; Sammel MD; Bradbury AR; Daly M; Karlan B; Rubin SC
Gynecol Oncol; 2011 Dec; 123(3):486-91. PubMed ID: 21945552
[TBL] [Abstract][Full Text] [Related]
23. Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial.
Cascinu S; Galizia E; Labianca R; Ferraù F; Pucci F; Silva RR; Luppi G; Beretta GD; Berardi R; Scartozzi M
Cancer Chemother Pharmacol; 2011 Jul; 68(1):37-43. PubMed ID: 20821330
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer.
Rom J; Bechstein S; Domschke C; Golatta M; Mayer C; Heil J; Thum J; Smetanay K; Windemuth-Kieselbach C; Wallwiener M; Marme F; Schuetz F; Sohn C; Schneeweiss A
Anticancer Drugs; 2014 Feb; 25(2):219-24. PubMed ID: 24247203
[TBL] [Abstract][Full Text] [Related]
25. Is it equivalent? Evaluation of the clinical activity of single agent Lipodox® compared to single agent Doxil® in ovarian cancer treatment.
Smith JA; Costales AB; Jaffari M; Urbauer DL; Frumovitz M; Kutac CK; Tran H; Coleman RL
J Oncol Pharm Pract; 2016 Aug; 22(4):599-604. PubMed ID: 26183293
[TBL] [Abstract][Full Text] [Related]
26. Kinetic targeting of pegylated liposomal doxorubicin: a new approach to reduce toxicity during chemotherapy (CARL-trial).
Eckes J; Schmah O; Siebers JW; Groh U; Zschiedrich S; Rautenberg B; Hasenburg A; Jansen M; Hug MJ; Winkler K; Pütz G
BMC Cancer; 2011 Aug; 11():337. PubMed ID: 21816044
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.
Gabizon A; Shmeeda H; Barenholz Y
Clin Pharmacokinet; 2003; 42(5):419-36. PubMed ID: 12739982
[TBL] [Abstract][Full Text] [Related]
28. [Doxil--pegylated liposomal doxorubicin].
Sekiya N; Imamura A
Gan To Kagaku Ryoho; 2008 Aug; 35(8):1439-43. PubMed ID: 18701868
[TBL] [Abstract][Full Text] [Related]
29. Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer.
Richards DA; Loesch D; Vukelja SJ; Wu H; Hyman WJ; Nieves J; Wang Y; Hu S; Shonukan OO; Tai DF
Invest New Drugs; 2011 Oct; 29(5):963-70. PubMed ID: 20352294
[TBL] [Abstract][Full Text] [Related]
30. An overview of doxorubicin formulations in cancer therapy.
Rivankar S
J Cancer Res Ther; 2014; 10(4):853-8. PubMed ID: 25579518
[TBL] [Abstract][Full Text] [Related]
31. Randomized single-agents trials in recurrent epithelial ovarian cancer.
Sessa C; Marsoni S
Int J Gynecol Cancer; 2005; 15 Suppl 3():247-51. PubMed ID: 16343240
[TBL] [Abstract][Full Text] [Related]
32. Phase I clinical trial of topotecan and pegylated liposomal doxorubicin.
Garcia AA; Roman L; Muderspach L; O'meara A; Facio G; Edwards S; Burnett A
Cancer Invest; 2005; 23(8):665-70. PubMed ID: 16377584
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
Rose PG; Blessing JA; Lele S; Abulafia O
Gynecol Oncol; 2006 Aug; 102(2):210-3. PubMed ID: 16478630
[TBL] [Abstract][Full Text] [Related]
34. Pegylated liposomal doxorubicin as single-agent treatment of low-grade non-Hodgkin's lymphoma: a phase II multicenter study.
Di Bella NJ; Khan MM; Dakhil SR; Logie KW; Marsland TA; Weinstein RE; Mirabel MY; Asmar L
Clin Lymphoma; 2003 Mar; 3(4):235-40. PubMed ID: 12672273
[TBL] [Abstract][Full Text] [Related]
35. Intertrigo-like dermatitis with pegylated liposomal doxorubicin: diagnosis and management.
Najem A; Deregnaucourt D; Ramdane S; Dridba M; Djouba F; Vercambre-Darras S
J Clin Oncol; 2014 Nov; 32(31):e104-6. PubMed ID: 24550424
[No Abstract] [Full Text] [Related]
36. Liposomal doxorubicin as targeted delivery platform: Current trends in surface functionalization.
Makwana V; Karanjia J; Haselhorst T; Anoopkumar-Dukie S; Rudrawar S
Int J Pharm; 2021 Jan; 593():120117. PubMed ID: 33259901
[TBL] [Abstract][Full Text] [Related]
37. Leakage kinetics of the liposomal chemotherapeutic agent Doxil: The role of dissolution, protonation, and passive transport, and implications for mechanism of action.
Russell LM; Hultz M; Searson PC
J Control Release; 2018 Jan; 269():171-176. PubMed ID: 29122661
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and pharmacodynamics evaluation of a thermosensitive chitosan based hydrogel containing liposomal doxorubicin.
Ren S; Dai Y; Li C; Qiu Z; Wang X; Tian F; Zhou S; Liu Q; Xing H; Lu Y; Chen X; Li N
Eur J Pharm Sci; 2016 Sep; 92():137-45. PubMed ID: 27388491
[TBL] [Abstract][Full Text] [Related]
39. Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients.
Ko EM; Lippmann Q; Caron WP; Zamboni W; Gehrig PA
Gynecol Oncol; 2013 Dec; 131(3):683-8. PubMed ID: 24096112
[TBL] [Abstract][Full Text] [Related]
40. MeSH-Informed Enrichment Analysis and MeSH-Guided Semantic Similarity Among Functional Terms and Gene Products in Chicken.
Morota G; Beissinger TM; Peñagaricano F
G3 (Bethesda); 2016 Aug; 6(8):2447-53. PubMed ID: 27261003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]